Schedule 13G ownership disclosure

X4 Pharmaceuticals Inc

Common Stock, par value $0.001 per share · CUSIP: 98420X202

Event date: 2025-08-11

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Trails Edge Capital Partners, LP

    Shares: 2,317,153.00 · Class: 9.9%

  • Trails Edge Biotechnology Master Fund, LP

    Shares: 2,317,153.00 · Class: 9.9%

  • Ortav Yehudai

    Shares: 2,317,153.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001641172-25-024646
Form type
SCHEDULE 13G
Filer
Trails Edge Capital Partners, LP
CIK
CIK 2077247
Filed
Aug 18, 2025
Reporting period
Aug 11, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub